CARDIFF ONCOLOGY, INC. (CRDF) Net margin 2016–2025
CARDIFF ONCOLOGY, INC. (CRDF) net profit margin by fiscal year — reported net income divided by reported revenue.
-7732.0%FY2025 · since FY2016: -10287.7% → -7732.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -7732.0% | -1080.4 pp |
| FY2024 | -6651.7% | +1840.3 pp |
| FY2023 | -8492.0% | +1534.9 pp |
| FY2022 | -10026.9% | -2146.4 pp |
| FY2021 | -7880.5% | -2605.4 pp |
| FY2020 | -5275.1% | +1434.6 pp |
| FY2019 | -6709.7% | -2358.7 pp |
| FY2018 | -4351.1% | +577.0 pp |
| FY2017 | -4928.1% | +5359.7 pp |
| FY2016 | -10287.7% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More CRDF financial trends
CRDF RevenueCRDF Net incomeCRDF Gross profitCRDF Gross marginCRDF Operating incomeCRDF Operating marginCRDF Operating cash flowCRDF Free cash flowCRDF Capital expendituresCRDF Return on equityCRDF Stock buybacksCRDF Dividends paidCRDF Total assetsCRDF Total liabilitiesCRDF Shareholders’ equityCRDF overview →